Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
Madrigal Pharmaceuticals (Nasdaq: MDGL) will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 2:30 P.M.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Madrigal Pharmaceuticals (Nasdaq: MDGL) will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 2:30 P.M. ET. The presentation will be webcast live and can be accessed via the company’s Investor Relations Events page. A replay will be available after the event.
Details
News Market Reaction – MDGL
On Feb 24, the day this news came out, MDGL closed 0.50% above the previous close.
Data tracked by StockTitan Argus for the Feb 24 session.
Key Figures
- Conference date
- March 3, 2026
- TD Cowen 46th Annual Health Care Conference presentation date
- Presentation time
- 2:30 P.M. ET
- Scheduled time for conference webcast presentation
Historical Context
-
Reported strong 2025 Rezdiffra sales and cash balance alongside key pipeline progress.
-
Granted 2,749 RSUs to five new non-executive employees under 2025 Inducement Plan.
-
Exclusive global license for six siRNA programs targeting MASH with milestones and royalties.
-
Expanded MASH pipeline beyond 10 programs anchored by Rezdiffra via Ribo agreement.
-
Issued 5,861 RSUs to 21 new non-executive employees under the 2025 Inducement Plan.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CONSHOHOCKEN, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 2:30 P.M. ET.
The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events page. A replay of the webcast will be available after the event.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.